ACHN Achillion Pharmaceuticals, Inc.

4.13
-0.02  -0%
Previous Close 4.15
Open 4.12
Price To book 1.48
Market Cap 564.67M
Shares 136,723,000
Volume 693,024
Short Ratio 7.20
Av. Daily Volume 1,422,100

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
ACH-4471
C3 glomerulopathy (C3G)
Phase 2a ongoing. Updated data presented at EASL April 22, 2017.
JNJ-4178
Hepatitis C (HCV)
Phase 2 initiation announced April 6, 2017. Interim data due 2Q 2017.
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2b trial initiation announced November 30, 2016. Data due 2H 2017.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)

Latest News

  1. Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx
  2. Why Achillion Pharmaceuticals Stock Is Jumping 15% Today
  3. Achillion: It Can't Get Any Worse…Or Can It?
  4. Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : May 11, 2017
  5. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : May 10, 2017
  6. Achillion (ACHN) Reports Wider-than-Expected Loss in Q1
  7. Achillion reports 1Q loss
  8. Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
  9. Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
  10. ETFs with exposure to Achillion Pharmaceuticals, Inc. : April 25, 2017
  11. Why Achillion Pharmaceuticals Stock Sank on Monday
  12. Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA
  13. Why Achillion Pharmaceuticals, Noble Corp., and RLJ Lodging Trust Slumped Today
  14. Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
  15. If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
  16. Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
  17. Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals
  18. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : March 30, 2017
  19. Why Is Achillion (ACHN) Down 11.3% Since the Last Earnings Report?
  20. USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors